In developing next generation cryopreservation methods, technological breakthroughs shape the biopreservation industry. Cryoprotectants and controlled-rate freezing increase cell and tissue preservation, reducing damage and maximizing post-thaw viability. These advances are essential for storing and transporting stem cells, tissues, and biofluids for research and therapeutic use.
Automation of biopreservation systems is a market trend. Automated systems precisely manage temperature, humidity, and other conditions, assuring biopreservation reproducibility and consistency. Biopreservation workflow automation improves productivity and decreases human error, ensuring consistent results. This tendency is important in large-scale biobanking and high-throughput research.
Regulatory compliance and quality assurance in biopreservation are emerging industry priorities. As clinical demand for biopreserved materials develops, strict regulatory criteria must be met. GMP-compliant biopreservation technologies gain popularity, reassuring academics, doctors, and biopharmaceutical businesses of biological specimen quality and integrity.
The biopreservation industry is shifting toward customized preservation solutions due to the rise of personalized medicine and regenerative medicines. Custom cryopreservation procedures for specific cell types, tissues, or medicinal uses are growing. This strategy optimizes preservation conditions for varied biological materials, advancing precision medicine and cell-based therapeutics.
In developed and emerging countries, biopreservation options are growing. The global increase of biobanking, stem cell research, and biopharmaceutical development drives market adoption. Biopreservation methods are increasingly essential to research and healthcare infrastructures, providing high-quality biological resources for scientific and therapeutic use.
Technology developers, biobanking facilities, and research institutes are collaborating and partnering in the biopreservation business. Collaborative initiatives target standardization, scalability, and innovative biopreservation methods. These agreements drive biopreservation technologies from lab to field, growing the industry.
Despite these favorable developments, the Biopreservation industry faces hurdles include optimizing cryopreservation techniques for difficult cell types and developing standardized processes for emergent applications. Addressing these problems via research and collaboration will help biopreservation technologies evolve to meet the changing requirements of the scientific and medical communities.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Presence and recent merger and acquisition activities by market players and growing number of sperm and egg banks |
The Biopreservation market is expected to reach USD 6.01 Billion at a CAGR 11.5% during the forecast period 2023-2032. Biopreservation is a use of natural flora and its antibacterial products to preserve biological material. Biopreservation is playing an important role in healthcare and food industry to preserve the biological material or food product for a long time.
The increasing expenditure on healthcare, growing demand for stem cell preservation and awareness about its use with regards to treatment of diseases are expected to drive the growth of the market. Moreover, increasing awareness about personalized medicines and its applications are contributing to the growth of the biopreservation market. According to the US Food and Drug Administration (FDA), The department has approved 16 personalized medicines in the year 2017, which accounts for 20% of total drug approvals.
The rising high price of biopreservation instruments and its maintenance, stability issues related to the specimen and lack of skilled personnel for handling the biopreservation process may hamper the growth of the market during the assessment period.
The biopreservation market has been segmented on the basis of product, biospecimen, and application.
On the basis of product, the market has been classified as media and equipment. The media subsegment has been further divided into nutrient media, sera, and growth factors and supplements. The equipment segment has been further divided into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems segment has been further classified as freezers, cryogenic storage systems, thawing equipment, and refrigerators.
The biospecimen segment has been divided into human tissue samples, organs, stem cells, and other biospecimens.
The market, by source, has been segmented into regenerative medicine, biobanking, and drug discovery. On basis of regenerative medicine, the market has been divided into cell therapy, gene therapy, and others. Biobanking segment includes human egg, human sperm, and veterinary IVF.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biopreservation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The biopreservation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
The Americas are likely to dominate the global biopreservation market owing to the adoption of advanced technology, increasing spending on healthcare R&D, the presence of a well-established healthcare system, and increasing in-house sample storage in hospitals and research institutes. Moreover, presence and recent merger and acquisition activities by market players in the region are contributing to the growth of the market. For instance, in 2017, Cesca Therapeutics Inc. has acquired Sacramento’s SynGen Inc. for USD 1 million with this acquisition company has managed to add cell separation and cord blood processing products in their portfolio.
The European market is expected to be the second-largest biopreservation market. The market growth in this region can be attributed to the increasing number of births and with-it continuous increase in demand for umbilical cord preservation. According to the European Commission, in the year 2016 more than 5.1 million babies were born in Europe. Moreover, a growing number of sperm and egg banks is contributing to the growth of the market in this region.
Asia-Pacific is expected to be the fastest-growing biopreservation market during the forecast period owing to the increasing population in the region, increasing awareness about stem cell preservation and continuous development in the healthcare sector due to government funding.
The market in the Middle East & Africa is expected to account for the smallest share of the global biopreservation market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)